For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Semaglutide

Also known as: Semaglutide (GLP-1 agonist)

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.

Real-time market data

Pricing for Semaglutide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$9.31/mg

range $1.00–$44.70/mg

Sellers

62

from $0.00

45-day trend

+18.2%

vs 45-day avg $/mg

55 of 62 sellers have a current price· 44 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Semaglutide

153 third-party tests across 20 vendors. Each card links to the full report.

All 153 COAs for Semaglutide →
Measured purity 99.0%–100.0% across 97 COAs
Measured purity over time
✓ Vendor-published
99.94 %
Jun 2026
TrustPointe Analytics Moderate

For

Semaglutide

by Peptide Partners· batch SPL-4149

COA on file
Aggregated · 3rd-party listing
99.07 %
Jun 2026
ILS Labs Strong

For

Semaglutide

by Peptide Plugs· batch 125-01-SM

Aggregated · 3rd-party listing
99.75 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

✓ Vendor-published
99.63 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

COA on file
Aggregated · 3rd-party listing
99.23 %
May 2026
Horizon Analytical

For

Semaglutide

by Pepsgpt· batch P-2885342-P

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3022026SM

Aggregated · 3rd-party listing
99.75 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3142026SM

Aggregated · 3rd-party listing
99.17 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2242026SM

✓ Vendor-published
99.96 %
Apr 2026
Kovera Labs

For

ION-1S

by Ion Peptide· batch ION1S20-04172026

COA on file
Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

Semaglutide

by OROS Research· batch OR-LPGLPS10-426-B3

Aggregated · 3rd-party listing
99.68 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3272026SM

Aggregated · 3rd-party listing
99.63 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3222026SX

Aggregated · 3rd-party listing
99.80 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

Semaglutide

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.41 %
Mar 2026
AccumarkLabs Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2182026SM

Aggregated · 3rd-party listing
99.02 %
Mar 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Prime Peptides· batch 2122026SM

Aggregated · 3rd-party listing
99.83 %
Mar 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Orbitrex Peptides· batch 1G200426

Aggregated · 3rd-party listing
99.45 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Qihang Peptide· batch 3

✓ Vendor-published
99.76 %
Feb 2026
Vanguard Laboratory Strong

For

Semaglutide

by Reta One Labs· batch SM100326

COA on file
✓ Vendor-published
99.31 %
Feb 2026
Vanguard Laboratory Strong

For

Semaglutide

by Reta One Labs· batch SM200326

COA on file
Aggregated · 3rd-party listing
99.81 %
Feb 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P0502152026-01

✓ Vendor-published
99.81 %
Feb 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P0502152026-01

COA on file
Aggregated · 3rd-party listing
99.76 %
Feb 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Reta One Labs· batch SM100326

Aggregated · 3rd-party listing
99.31 %
Feb 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Reta One Labs· batch SM200326

Aggregated · 3rd-party listing
99.52 %
Feb 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 1052026SM

Research depth

23 citations indexed for Semaglutide

All research on Semaglutide →

rct · 2027

SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.

cohort · 2026

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials

Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.

Study · 2026

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate

Background and hypothesis Semaglutide is a glucagon-like peptide-1 receptor agonist widely used for its glucose-lowering effects in people with type 2 diabetes (T2D), as well as its cardiovascular and kidney-protective properties.

rct · 2026

Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial

Importance Consistent results from preclinical and clinical studies indicate that activation of glucagon-like peptide-1 receptors (GLP-1 Rs) affects reward processes; however, to our knowledge, no study has previously evaluated whether a GLP-1 R agonist (GLP-1 RA) affects motivated behavior in individuals with major de…

Study · 2026

High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insufficient insulin secretion or impaired cellular response to insulin, resulting in increased blood sugar levels and persistent hyperglycemia.

review · 2026

The risk of retinal vascular events in patients using semaglutide: a scoping review

Background This scoping review aims to explore existing clinical trials on the association between semaglutide use and the occurrence of retinal vascular events to detect any potential safety concern.